Company: ICUI
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0000883984-25-000010
Chunk: 16

Company: ICU MEDICAL INC/DE
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 16
---

| (in millions, except per share and stock price amounts) |     |   |    2024 |     |   |    2023 |     |     | Change |   |
|:--------------------------------------------------------|:----|:--|--------:|:----|:--|--------:|:----|:----|-------:|:--|
| Revenue                                                 |     | $ | 2,382.0 |     | $ | 2,259.1 |     |     |    5.4 | % |
| Net Loss                                                |     | $ |  -118.0 |     | $ |   -29.7 |     |     | -297.3 | % |
| Adjusted EBITDA(1)                                      |     | $ |   370.5 |     | $ |   376.1 |     |     |   -1.5 | % |
| Diluted loss per share (EPS)                            |     | $ |   -4.83 |     | $ |   -1.23 |     |     | -292.7 | % |
| Adjusted Diluted EPS(2)                                 |     | $ |    6.21 |     | $ |    6.75 |     |     |   -8.0 | % |
| Operating cash flow                                     |     | $ |   204.0 |     | $ |   166.2 |     |     |   22.7 | % |
| Free Cash Flow(3)                                       |     | $ |   125.4 |     | $ |    83.8 |     |     |   49.6 | % |
| Closing Stock Price at Fiscal Year-end                  |     | $ |  155.17 |     | $ |   99.74 |     |     |   55.6 | % |

___________________________

(1) Adjusted EBITDA adjusts from net income certain items as described in Annex A to this proxy statement. Our reconciliation of net loss to Adjusted EBITDA is contained in Annex A to this proxy statement.

(2) Adjusted Diluted EPS represents diluted earnings per share adjusted for certain items as described in Annex A to this proxy statement. Our reconciliation of diluted earnings per share to Adjusted Diluted EPS is contained in Annex A to this proxy statement.

<div align='center'>13</div>

(3) Free Cash Flow